RBC reiterated Santarus at outperform

Santarus Inc. was reiterated at outperform, speculative risk, by RBC Capital Markets analyst Douglas Miehm. The company reported better-than-expected second-quarter loss of $0.36 per share, compared to a loss of $0.54 per share in the prior-year period and higher than the analyst's and consensus forecasts of a loss of $0.45 per share. Sales of Zegerid totaled $8.7 million in the quarter, up 281% from $3.1 million in the second-quarter 2005. Shares of the San Diego-based pharmaceutical company were up 66 cents, or 13.04%, at $5.72, on volume of 2,032,086 shares versus the three-month running average of 469,818 shares. (Nasdaq: SNTS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.